| Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice JF De Groot, G Fuller, AJ Kumar, Y Piao, K Eterovic, Y Ji, CA Conrad Neuro-oncology 12 (3), 233-242, 2010 | 599 | 2010 |
| The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers L Han, L Diao, S Yu, X Xu, J Li, R Zhang, Y Yang, HMJ Werner, ... Cancer cell 28 (4), 515-528, 2015 | 495 | 2015 |
| Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults N Jain, KG Roberts, E Jabbour, K Patel, AK Eterovic, K Chen, ... Blood, The Journal of the American Society of Hematology 129 (5), 572-581, 2017 | 393 | 2017 |
| The neutrophil-to-lymphocyte ratio: a narrative review SS Faria, PC Fernandes Jr, MJB Silva, VC Lima, W Fontes, ... ecancermedicalscience 10, 2016 | 374 | 2016 |
| Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy AK Lucio-Eterovic, Y Piao, JF De Groot Clinical cancer research 15 (14), 4589-4599, 2009 | 288 | 2009 |
| Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis E Shoshan, AK Mobley, RR Braeuer, T Kamiya, L Huang, ME Vasquez, ... Nature cell biology 17 (3), 311-321, 2015 | 241 | 2015 |
| Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time … CA Scrideli, CG Carlotti, OK Okamoto, VS Andrade, MAA Cortez, ... Journal of neuro-oncology 88, 281-291, 2008 | 233 | 2008 |
| Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas AKB Lucio-Eterovic, MAA Cortez, ET Valera, FJN Motta, RGP Queiroz, ... BMC cancer 8, 1-10, 2008 | 221 | 2008 |
| Characterization of human cancer cell lines by reverse-phase protein arrays J Li, W Zhao, R Akbani, W Liu, Z Ju, S Ling, CP Vellano, P Roebuck, Q Yu, ... Cancer cell 31 (2), 225-239, 2017 | 219 | 2017 |
| Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ... Science translational medicine 9 (392), eaal5148, 2017 | 214 | 2017 |
| Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Y Xing, NU Lin, MA Maurer, H Chen, A Mahvash, A Sahin, A Akcakanat, ... Breast Cancer Research 21, 1-12, 2019 | 209 | 2019 |
| A decision support framework for genomically informed investigational cancer therapy F Meric-Bernstam, A Johnson, V Holla, AM Bailey, L Brusco, K Chen, ... Journal of the National Cancer Institute 107 (7), djv098, 2015 | 205 | 2015 |
| Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol F Meric-Bernstam, L Brusco, M Daniels, C Wathoo, AM Bailey, L Strong, ... Annals of Oncology 27 (5), 795-800, 2016 | 197 | 2016 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 186 | 2020 |
| Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology IW Deveson, B Gong, K Lai, JS LoCoco, TA Richmond, J Schageman, ... Nature biotechnology 39 (9), 1115-1128, 2021 | 175 | 2021 |
| Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function AK Lucio-Eterovic, MM Singh, JE Gardner, CS Veerappan, JC Rice, ... Proceedings of the National Academy of Sciences 107 (39), 16952-16957, 2010 | 169 | 2010 |
| Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers Y Wang, X Xu, S Yu, KJ Jeong, Z Zhou, L Han, YH Tsang, J Li, H Chen, ... Genome research 27 (7), 1112-1125, 2017 | 168 | 2017 |
| Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations T Dogruluk, YH Tsang, M Espitia, F Chen, T Chen, Z Chong, V Appadurai, ... Cancer research 75 (24), 5341-5354, 2015 | 163 | 2015 |
| Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set J Roszik, LE Haydu, KR Hess, J Oba, AY Joon, AE Siroy, TV Karpinets, ... BMC medicine 14, 1-8, 2016 | 128 | 2016 |
| Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis YW Kim, D Koul, SH Kim, AK Lucio-Eterovic, PR Freire, J Yao, J Wang, ... Neuro-oncology 15 (7), 829-839, 2013 | 108 | 2013 |
Gordon MillsOregon Health & Science University在 ohsu.edu 的电子邮件经过验证
